SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, announces the appointment of Dr David Chiswell, PhD, OBE, as Chair of the Board.
Dr David Chiswell is one of the UK’s most successful biotechnology executives, with extensive experience in the development of early stage biotechnology companies during 30 years in the industry.
He joins the SENISCA Board having cofounded Cambridge Antibody Technology (CAT) in 1990 and served as its Chief Executive Officer (CEO) from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq.
He also served as CEO of Nabriva Therapeutics from 2009 to 2012, following which he was appointed as CEO of Kymab Ltd from 2015 to 2018.
Dr Chiswell currently serves as Chair of Epsilogen and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund.
Dr Chiswell has served as the Chair of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chair of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006.
Dr Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr Chiswell to our Board at SENISCA. His deep knowledge and expertise in the biotechnology sector – particularly in early-stage companies, combined with his strategic expertise will be crucial as we continue our evolution towards becoming a clinical stage biotechnology company developing novel senotherapeutics to treat age-related disease."
"Our ability to attract someone of David’s calibre speaks volumes about the quality of our science and the strong foundational work our team has undertaken.”
Dr David Chiswell, Chair of the Board of SENISCA commented: “SENISCA is a revolutionary company with the potential to transform the landscape of senotherapeutic treatments."
"I am thrilled to be joining the company as Chair and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”